[{"id":"d69d9e8b-481b-4b6a-a241-66952601f3da","acronym":"RITZ","url":"https://clinicaltrials.gov/study/NCT05735834","created_at":"2023-02-21T16:01:53.200Z","updated_at":"2025-02-25T14:03:19.754Z","phase":"Phase 3","brief_title":"Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients","source_id_and_acronym":"NCT05735834 - RITZ","lead_sponsor":"International Extranodal Lymphoma Study Group (IELSG)","biomarkers":" MYD88 • CCND1 • BCL6 • IL2RA • MME • ITGAE • ISG20","pipe":" | ","alterations":" IL2RA expression","tags":["MYD88 • CCND1 • BCL6 • IL2RA • MME • ITGAE • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IL2RA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Brukinsa (zanubrutinib) • Truxima (rituximab-abbs)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 05/21/2024","start_date":" 05/21/2024","primary_txt":" Primary completion: 05/01/2029","primary_completion_date":" 05/01/2029","study_txt":" Completion: 05/01/2029","study_completion_date":" 05/01/2029","last_update_posted":"2025-02-19"},{"id":"543ff654-46d9-4c7b-81b4-7196e38ce6fb","acronym":"","url":"https://clinicaltrials.gov/study/NCT05471271","created_at":"2022-07-22T11:56:25.671Z","updated_at":"2024-07-02T16:35:05.990Z","phase":"","brief_title":"IL-2 PET Imaging in Advanced Solid Tumours","source_id_and_acronym":"NCT05471271","lead_sponsor":"University Medical Center Groningen","biomarkers":" IL2","pipe":" | ","alterations":" IL2RA expression","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IL2RA expression"],"overall_status":"Recruiting","enrollment":" Enrollment 14","initiation":"Initiation: 10/02/2023","start_date":" 10/02/2023","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2024-05-03"},{"id":"c80dda17-2bdc-4783-9fe5-a49313fb46d2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05139004","created_at":"2021-12-01T15:53:46.640Z","updated_at":"2024-07-02T16:35:21.820Z","phase":"Phase 1","brief_title":"90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome","source_id_and_acronym":"NCT05139004","lead_sponsor":"City of Hope Medical Center","biomarkers":" FLT3 • NPM1 • IL2RA • ISG20","pipe":" | ","alterations":" MLL rearrangement • IL2RA expression • Chr t(9;11)","tags":["FLT3 • NPM1 • IL2RA • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • IL2RA expression • Chr t(9;11)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e melphalan • fludarabine IV • Kepivance (palifermin)"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 07/19/2022","start_date":" 07/19/2022","primary_txt":" Primary completion: 12/13/2024","primary_completion_date":" 12/13/2024","study_txt":" Completion: 12/13/2024","study_completion_date":" 12/13/2024","last_update_posted":"2024-01-30"},{"id":"5206abc5-f3bf-41df-978b-3fe0011087ec","acronym":"","url":"https://clinicaltrials.gov/study/NCT05504408","created_at":"2022-08-17T13:55:03.907Z","updated_at":"2024-07-02T16:35:34.127Z","phase":"","brief_title":"Observational Study for the Evaluation of Incidence of Systemic Mastocytosis in t(8;21) Acute Myeloid Leukemia","source_id_and_acronym":"NCT05504408","lead_sponsor":"The First Affiliated Hospital of Soochow University","biomarkers":" TNFRSF8 • IL2RA • CD2 • ISG20","pipe":" | ","alterations":" TNFRSF8 expression • IL2RA expression","tags":["TNFRSF8 • IL2RA • CD2 • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression • IL2RA expression"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 09/01/2022","start_date":" 09/01/2022","primary_txt":" Primary completion: 08/31/2024","primary_completion_date":" 08/31/2024","study_txt":" Completion: 08/31/2024","study_completion_date":" 08/31/2024","last_update_posted":"2023-10-10"},{"id":"a007902a-0a7f-41d6-85c9-d3d6c51f4f3e","acronym":"","url":"https://clinicaltrials.gov/study/NCT02689453","created_at":"2021-01-18T13:07:06.175Z","updated_at":"2024-07-02T16:36:11.245Z","phase":"Phase 1","brief_title":"Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)","source_id_and_acronym":"NCT02689453","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD8 • TNFRSF8 • CCR4 • IL2RA • CD4 • NCAM1 • CCR7 • CD52 • FAS • ISG20","pipe":" | ","alterations":" IL2RA expression","tags":["CD8 • TNFRSF8 • CCR4 • IL2RA • CD4 • NCAM1 • CCR7 • CD52 • FAS • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IL2RA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Campath (alemtuzumab) • rhIL-15"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 01/19/2017","start_date":" 01/19/2017","primary_txt":" Primary completion: 06/15/2021","primary_completion_date":" 06/15/2021","study_txt":" Completion: 06/15/2021","study_completion_date":" 06/15/2021","last_update_posted":"2022-04-29"},{"id":"3b7aa45c-07ba-4421-ad73-bd3b53ea28b2","acronym":"","url":"https://clinicaltrials.gov/study/NCT00425672","created_at":"2021-01-18T01:29:59.629Z","updated_at":"2024-07-02T16:37:04.882Z","phase":"Phase 1/2","brief_title":"ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment","source_id_and_acronym":"NCT00425672","lead_sponsor":"University of Washington","biomarkers":" IL2RA","pipe":" | ","alterations":" IL2RA expression • IL2 expression","tags":["IL2RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IL2RA expression • IL2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ontak (denileukin diftitox)"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 09/01/2005","start_date":" 09/01/2005","primary_txt":" Primary completion: 04/01/2010","primary_completion_date":" 04/01/2010","study_txt":"","study_completion_date":"","last_update_posted":"2018-12-05"},{"id":"8812c060-335b-47a4-a245-7497912ecdcd","acronym":"","url":"https://clinicaltrials.gov/study/NCT00080535","created_at":"2021-01-18T00:13:21.794Z","updated_at":"2024-07-02T16:37:14.422Z","phase":"Phase 2","brief_title":"Anti-Tac(Fv)-PE38 (LMB-2) to Treat Cutaneous T-Cell Lymphomas","source_id_and_acronym":"NCT00080535","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IL2RA","pipe":" | ","alterations":" IL2RA expression","tags":["IL2RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IL2RA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LMB-2"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 04/30/2004","start_date":" 04/30/2004","primary_txt":" Primary completion: 12/31/2011","primary_completion_date":" 12/31/2011","study_txt":" Completion: 12/31/2011","study_completion_date":" 12/31/2011","last_update_posted":"2018-01-29"},{"id":"c4090cb9-14c2-4c40-bba0-1b390a98222c","acronym":"","url":"https://clinicaltrials.gov/study/NCT00513188","created_at":"2021-01-18T01:50:50.941Z","updated_at":"2024-07-02T16:37:27.039Z","phase":"","brief_title":"Combination Chemotherapy and Denileukin Diftitox in Treating Patients With Newly Diagnosed T-Cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT00513188","lead_sponsor":"University of Miami","biomarkers":" IL2RA • ISG20","pipe":" | ","alterations":" IL2RA expression","tags":["IL2RA • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IL2RA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • leucovorin calcium • Ontak (denileukin diftitox)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 02/01/2007","start_date":" 02/01/2007","primary_txt":" Primary completion: 06/01/2008","primary_completion_date":" 06/01/2008","study_txt":"","study_completion_date":"","last_update_posted":"2016-12-15"}]